Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105 | Active Not Recruiting Phase 1 FDA Drug

• 1 other identifier: 00-006
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 3

Brief Summary

A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV coronavirus infection, or resultant from influenza virus infection.

Conditions

ARDS, Human; Covid19

Outcome Measures

Primary Outcomes (8)

• Incidence of Treatment-Emergent Serious Adverse Events

  Incidence of treatment-emergent serious adverse events (TE-SAEs) within 4 weeks after treatment, defined as one or more of the following untoward medical occurrences happening within the first 4 weeks after treatment. i. Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). ii. Event requiring inpatient hospitalization or prolongation of existing hospitalization (e.g., for worsening dyspnea). iii. Event resulting in persistent or significant disability/incapacity. iv. Event resulting in death. v. Event leading to other clinically significant untoward laboratory test result(s) or medical condition(s), as determined by the Investigator.

  Within 4 weeks after treatment

• Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.

  Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.

  Baseline to 6 Months

• Number of Participants with Changes in Echocardiography Overall Assessment

  Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 months, this change in overall assessment will be the outcome in numbers of particants with a change.

  Baseline to 6 Months

• Number of Participants with Changes to overall assessment of Electrocardiogram

  Number of Participants with changes to Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 Months

  Baseline to 6 Months

• Time to recovery of Sp02

  Time to recovery of Sp02 to 90% or higher on room air (or the oxygen concentration the patient had before acute illness) after 10 minutes of spontaneous breathing.

  Baseline to 6 Months

• Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.

  Number of Participants with Abnormal Clinical Significant Lab Values in Blood Chemistry testing will be assessed at Baseline and 6 Months.

  Baseline to 6 months

• Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.

  Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation testing will be assessed at Baseline and 6 Months.

  Baseline to 6 months

• Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis

  Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.

  Baseline to 6 months

Secondary Outcomes (3)

• Immunity

  Baseline to 6 Months

• Change in Imaging via X-ray

  Baseline to 6 Months

• Change in Imaging via Computerized Tomography

  Baseline to 6 Months

Study Arms (4)

Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs)

ACTIVE COMPARATOR

Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs.

Biological: Longeveron Mesenchymal Stem Cells (LMSCs)

Cohort (SARS-CoV-2): Arm 2 (Placebo)

PLACEBO COMPARATOR

Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 2: 10 subjects treated with up to 3 doses of Placebo.

Other: Placebo

Cohort 2 (Flu): Arm 3 (LMSCs)

ACTIVE COMPARATOR

Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs.

Biological: Longeveron Mesenchymal Stem Cells (LMSCs)

Cohort 2 (Flu): Arm 4 (Placebo)

PLACEBO COMPARATOR

Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 4: 10 subjects treated with up to 3 doses of Placebo.

Other: Placebo

Interventions

Longeveron Mesenchymal Stem Cells (LMSCs) BIOLOGICAL

Longeveron Mesenchymal Stem Cells (LMSCs)

Cohort 1 (SARS-CoV-2): Arm 1 (LMSCs); Cohort 2 (Flu): Arm 3 (LMSCs)

Placebo OTHER

Placebo

Cohort (SARS-CoV-2): Arm 2 (Placebo); Cohort 2 (Flu): Arm 4 (Placebo)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female or any race or ethnicity.
• At least 18 years of age.
• Provide written informed consent. For subjects who are incapable of providing informed consent, written informed consent can be provided on behalf of the subject by a legally authorized representative (LAR).
• Diagnosis of mild to severe ARDS per the Berlin Definition of ARDS. More specifically, the following 3 conditions must be present.
• A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio \< 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP). A patient may be included if the PaO2/FiO2 ratio \< 200 with \< 8 cm H2O PEEP if there is a contraindication to increased PEEP (evidence of barotrauma).
• Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph.
• No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.
• Confirmed diagnosis of infection with coronavirus or influenza virus.
• Willing to perform all assessments required for the study.
• Must agree to the collection of all blood samples per protocol.
• Must agree to have samples stored and used for secondary research.

You may not qualify if:

• Patient receiving Extracorporeal Membrane Oxygenation (ECMO).
• History of malignancy within previous 2.5 years, except for curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ, or cervical carcinoma.
• Prior positive test for any of the following without demonstration of resolution.
• i. Hepatitis B virus (HBV) surface antigen (HBsAg). ii. Viremic hepatitis C virus (HCV). iii. Human immunodeficiency virus-1 or -2 (HIV1 or 2 HIV2). iv. Human T-cell leukemia virus-I or -II (HTLV-I or HTLV-II). v. Syphilis.
• Female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.
• Known hypersensitivity to dimethyl sulfoxide (DMSO).
• Be an organ transplant recipient, other than for corneal, bone, skin, ligament, or tendon transplant.
• Actively listing (or expected listing) for transplant of any organ, other than for corneal, bone, skin, ligament, or tendon transplant.
• Continuous use of any medication at immunosuppressive dosing for greater than 14 consecutive days over the past 3 months.
• Currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial. However, use of hydroxychloroquine, remdesivir, lopinavir/ritonavir and ivermectin are allowed as well as convalescent plasma.. Exceptions for other experimental interventions related to treating the patient's acute illness may be made with prior approval of Longeveron.
• Any serious comorbid illness or any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study, or that may compromise the validity of the study.

Sponsors & Collaborators

• Longeveron Inc.: lead

Study Sites (3)

Miami VA Healthcare System

Miami, Florida, 33125, United States

Location

University of Maryland Medical Center

Baltimore, Maryland, 21201, United States

Location

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome; COVID-19

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Respiration Disorders; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Double-blinded, randomized, placebo-controlled study with 2 cohorts. Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 2: 10 subjects treated with up to 3 doses of Placebo. Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 4: 10 subjects treated with up to 3 doses of Placebo. Each subject will be intravenously infused with 100 million LMSCs or placebo on Day 0. If no treatment-related AEs are seen after the infusion, a second infusion will be given on Day 3. If no treatment-related AEs are seen after the second infusion, a third infusion will be given Day 6. Follow-up visits will be conducted: daily until hospital discharge; at Week 4 after treatment (with LMSCs or placebo) for patients already discharged; and at Month 6 after treatment (with LMSCs or placebo).

Study Record Dates

• First Submitted: September 29, 2020
• First Posted: November 16, 2020
• Study Start: July 24, 2020
• Primary Completion: June 1, 2024
• Study Completion: July 1, 2025
• Last Updated: February 20, 2024

Record last verified: 2024-02

Locations

US (3)